Choroideremia Overview
Learn About Choroideremia
Choroideremia is a condition characterized by progressive vision loss that mainly affects males. The first symptom of this condition is usually an impairment of night vision (night blindness), which can occur in early childhood. A progressive narrowing of the field of vision (tunnel vision) follows, as well as a decrease in the ability to see details (visual acuity). These vision problems are due to an ongoing loss of cells (atrophy) in the specialized light-sensitive tissue that lines the back of the eye (retina) and a nearby network of blood vessels (the choroid). The vision impairment in choroideremia worsens over time, but the progression varies among affected individuals. However, all individuals with this condition will develop blindness, most commonly in late adulthood.
Mutations in the CHM gene cause choroideremia. The CHM gene provides instructions for producing the Rab escort protein-1 (REP-1). As an escort protein, REP-1 attaches to molecules called Rab proteins within the cell and directs them to the membranes of various cell compartments (organelles). Rab proteins are involved in the movement of proteins and organelles within cells (intracellular trafficking). Mutations in the CHM gene lead to an absence of REP-1 protein or the production of a REP-1 protein that cannot carry out its protein escort function. This lack of functional REP-1 prevents Rab proteins from reaching and attaching (binding) to the organelle membranes. Without the aid of Rab proteins in intracellular trafficking, cells die prematurely.
The prevalence of choroideremia is estimated to be 1 in 50,000 to 100,000 people. However, it is likely that this condition is underdiagnosed because of its similarities to other eye disorders. Choroideremia is thought to account for approximately 4 percent of all blindness.
Choroideremia is inherited in an X-linked recessive pattern. The CHM gene is located on the X chromosome, which is one of the two sex chromosomes. In males (who have only one X chromosome), one altered copy of the gene in each cell is sufficient to cause the condition. In females (who have two X chromosomes), a mutation must be present in both copies of the gene to cause the disorder. Males are affected by X-linked recessive disorders much more frequently than females. A characteristic of X-linked inheritance is that fathers cannot pass X-linked traits to their sons.
Jules Stein Eye Institute Medical Group
Michael Ip is an Ophthalmologist in Arcadia, California. Dr. Ip and is rated as a Distinguished provider by MediFind in the treatment of Choroideremia. His top areas of expertise are Retinal Vein Occlusion, Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Diabetic Macular Edema (DME), and Vitrectomy.
Northern California Retina Vitreous Associates
Jay Wang is an Ophthalmologist in Mountain View, California. Dr. Wang and is rated as an Advanced provider by MediFind in the treatment of Choroideremia. His top areas of expertise are Retinal Detachment, Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Vitrectomy, and Trabeculectomy.
Ucsf Medical Group Business Services
Jacque Duncan is an Ophthalmologist in Berkeley, California. Dr. Duncan and is rated as a Distinguished provider by MediFind in the treatment of Choroideremia. Her top areas of expertise are Usher Syndrome Type 2A, Usher Syndrome, Retinitis Pigmentosa, Retinopathy Pigmentary Mental Retardation, and Vitrectomy.
Summary: The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision. The mission of the VRAI is to enable the highest quality, standardized efficacy testing of patients with visual impairment. The VRAI facilitates the development and refinement of existing endpoints specifically for testing patien...
Summary: Studying the morphology and function of the normal and diseased retina in vivo is needed for advancing the detection, diagnosis, and treatment of retinal disease. This protocol uses an adaptive optics scanning laser ophthalmoscope (AOSLO) to image the normal and diseased retina with individual cellular resolution non-invasively. The primary objective of this study is to obtain and analyze high-res...
Published Date: July 01, 2013
Published By: National Institutes of Health